Globus Medical, Inc. (NYSE:GMED) Stock Has Average Target Price of $99.46 According to Analysts

Shares of Globus Medical, Inc. (NYSE:GMED) have been assigned a consensus rating of “Moderate Buy” from the seventeen ratings firms that are currently covering the firm, MarketBeat.com reports. Five investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and three have issued a strong buy rating on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $99.46.

A number of equities research analysts recently commented on the stock. Zacks Research upgraded shares of Globus Medical from a “hold” rating to a “strong-buy” rating in a report on Monday, August 10th. BTIG Research reaffirmed a “neutral” rating on shares of Globus Medical in a research note on Friday, September 18th. Royal Bank Of Canada lowered their target price on Globus Medical from $115.00 to $85.00 and set an “outperform” rating for the company in a report on Thursday, October 1st. Wells Fargo & Company lowered their target price on Globus Medical from $103.00 to $99.00 and set an “overweight” rating for the company in a report on Friday, August 7th. Finally, BMO Capital Markets began coverage on Globus Medical in a research note on Wednesday, July 8th. They issued an “outperform” rating and a $94.00 price target on the stock.

Globus Medical Price Performance

NYSE:GMED opened at $81.89 on Friday. Globus Medical has a fifty-two week low of $59.51 and a fifty-two week high of $101.40. The stock has a market capitalization of $10.99 billion, a PE ratio of 20.94, a price-to-earnings-growth ratio of 1.31 and a beta of 0.96. The business’s 50-day simple moving average is $78.18 and its 200-day simple moving average is $83.80.

Globus Medical (NYSE:GMED) last issued its quarterly earnings data on Thursday, August 6th. The medical device company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.10 by $0.24. The business had revenue of $789.61 million during the quarter, compared to analyst estimates of $782.88 million. Globus Medical had a return on equity of 14.57% and a net margin of 17.02%. Globus Medical’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.86 EPS. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. On average, research analysts expect that Globus Medical will post 4.99 earnings per share for the current year.

Insider Transactions at Globus Medical

In other news, Director James R. Tobin sold 30,000 shares of the company’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $74.58, for a total transaction of $2,237,400.00. Following the completion of the transaction, the director directly owned 15,000 shares of the company’s stock, valued at $1,118,700. This represents a 66.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Stephen Zarrilli sold 25,000 shares of the company’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $87.04, for a total value of $2,176,000.00. Following the transaction, the director directly owned 25,000 shares of the company’s stock, valued at $2,176,000. This represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 18.38% of the company’s stock.

Institutional Investors Weigh In On Globus Medical

Several institutional investors have recently bought and sold shares of GMED. Janus Henderson Group PLC raised its holdings in shares of Globus Medical by 4.5% in the first quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company’s stock valued at $656,831,000 after purchasing an additional 328,217 shares during the last quarter. Sculptor Capital LP lifted its position in shares of Globus Medical by 1.9% in the first quarter. Sculptor Capital LP now owns 3,058,000 shares of the medical device company’s stock worth $263,477,000 after purchasing an additional 58,000 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Globus Medical by 2.0% in the first quarter. Dimensional Fund Advisors LP now owns 1,769,897 shares of the medical device company’s stock worth $152,474,000 after purchasing an additional 33,976 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Globus Medical by 2.8% during the first quarter. The Manufacturers Life Insurance Company now owns 1,132,278 shares of the medical device company’s stock worth $97,557,000 after purchasing an additional 30,412 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its holdings in Globus Medical by 107.0% during the first quarter. Arrowstreet Capital Limited Partnership now owns 912,905 shares of the medical device company’s stock worth $78,656,000 after purchasing an additional 471,875 shares during the last quarter. Institutional investors own 95.16% of the company’s stock.

Globus Medical Company Profile

Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.

Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.